TE Anatoxal Berna and Telotristat Etiprate

• Generic Name: tetanus toxoid
• Dosage Forms: n.a.
• Other Brand Names:

Tetanus Toxoid is used to prevent tetanus (also known as lockjaw). Tetanus is a serious illness that causes convulsions (seizures) and severe muscle spasms that can be strong enough to cause bone fractures of the spine. Tetanus causes death in 30 to 40 percent of cases.

Immunization against tetanus is recommended for all infants 6 to 8 weeks of age and older, all children, and all adults. Immunization against tetanus consists first of a series of either 3 or 4 injections, depending on which type of tetanus toxoid you receive. In addition, it is very important that you get a booster injection every 10 years for the rest of your life. Also, if you get a wound that is unclean or hard to clean, you may need an emergency booster injection if it has been more than 5 years since your last booster. In recent years, two-thirds of all tetanus cases have been in persons 50 years of age and older. A tetanus infection in the past does not make you immune to tetanus in the future.

This vaccine is to be administered only by or under the supervision of your doctor or other health care professional.

• Generic Name: telotristat
• Dosage Forms: n.a.
• Other Brand Names: Xermelo

Used (in combination with somatostatin analog therapy) for treatment of carcinoid syndrome diarrhea inadequately controlled by somatostatin analog therapy alone (designated an orphan drug by FDA for the treatment of carcinoid syndrome in patients with neuroendocrine tumors).

Carcinoid syndrome, a condition associated with serotonin overproduction, is characterized by flushing, diarrhea, wheezing, occasionally congestive heart failure, and various other manifestations. Although somatostatin analogs (e.g., octreotide, lanreotide) are standard treatment for carcinoid syndrome and are effective initially in most patients, some patients may not respond adequately or may develop recurrent symptoms, including diarrhea, despite therapy.

In clinical studies, telotristat ethyl reduced the frequency of daily bowel movements in patients with carcinoid syndrome diarrhea. Reductions in other symptoms of carcinoid syndrome (e.g., abdominal pain, flushing) not observed.